Kevin Gordon Sells 11,500 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) Director Kevin Gordon sold 11,500 shares of Progyny stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the transaction, the director owned 6,792 shares in the company, valued at approximately $189,768.48. This trade represents a 62.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Progyny Stock Performance

PGNY traded up $0.50 during trading on Monday, hitting $27.85. The stock had a trading volume of 929,921 shares, compared to its average volume of 1,418,871. The firm has a market capitalization of $2.14 billion, a P/E ratio of 30.27, a PEG ratio of 1.89 and a beta of 0.99. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $33.06. The company’s 50-day moving average price is $28.71 and its 200 day moving average price is $24.03.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The company had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $349.05 million. During the same quarter last year, the business earned $0.19 EPS. The business’s revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities analysts expect that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.

Progyny announced that its Board of Directors has authorized a share buyback plan on Tuesday, May 26th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 10.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on PGNY shares. Truist Financial increased their target price on Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Jefferies Financial Group set a $33.00 price target on Progyny in a research note on Tuesday, September 8th. BTIG Research upped their price objective on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Citigroup reiterated an “outperform” rating on shares of Progyny in a research report on Tuesday, September 8th. Finally, Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.36.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PGNY. WINTON GROUP Ltd lifted its position in shares of Progyny by 266.7% during the 2nd quarter. WINTON GROUP Ltd now owns 251,834 shares of the company’s stock valued at $7,260,000 after acquiring an additional 183,163 shares during the period. Engineers Gate Manager LP grew its holdings in shares of Progyny by 5.6% in the 2nd quarter. Engineers Gate Manager LP now owns 152,757 shares of the company’s stock worth $4,404,000 after acquiring an additional 8,156 shares during the period. Integrated Wealth Concepts LLC purchased a new position in Progyny in the 2nd quarter valued at approximately $74,000. IFP Advisors Inc increased its stake in Progyny by 376.0% in the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock valued at $57,000 after purchasing an additional 1,549 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Progyny during the second quarter worth $1,705,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

About Progyny

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.